Fluorouracil

Generic Name: Fluorouracil

Brand Names: Actikerall, Carac, Efudex, Fluoroplex, Tolak

Drug Type: Small Molecule

Chemical Formula: C_₄H_₃FN_₂O_₂

CAS Number: 51-21-8

Unique Ingredient Identifier: U3P01618RT

Background: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

Indication: For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.

Associated Conditions: Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis

Associated Therapies: -

Clinical Trials

A Phase II Trial of Induction Chemotherapy With ND-420, Cisplatin and Fluorouracil Followed by Surgery in the Treatment of Patients With Localized Squamous Cell Carcinoma of the Esophagus

Phase 2

Terminated

Conditions: Localized Squamous Cell Carcinoma of the Esophagus

Interventions: Drug: ND-420
Procedure: Surgery
Drug: Cisplatin
Drug: fluorouracil

First Posted Date: 2013-12-23

Last Posted Date: 2020-05-20

Lead Sponsor: Nang Kuang Pharmaceutical Co., Ltd.

Target Recruit Count: 48

Registration Number: NCT02017600

Locations: 🇨🇳
Taipei Veterans General Hospital, Taipei, Taiwan

Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer

Phase 3

Withdrawn

Conditions: Esophageal Cancer

Interventions: Drug: Paclitaxel liposome
Drug: Cisplatin
Drug: 5-fluorouracil

First Posted Date: 2013-11-28

Last Posted Date: 2015-11-20

Lead Sponsor: Shantou University Medical College

Registration Number: NCT01998347

Locations: 🇨🇳
Department of medical oncology,Cancer hospital of Shantou University Medical colledge, Shantou, Guangdong, China

Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer

Interventions: Drug: Bevacizumb
Drug: 5-Fluorouracil
Drug: Epirubicin
Drug: Cyclophosphamide
Drug: Docetaxel

First Posted Date: 2013-11-15

Last Posted Date: 2015-10-08

Lead Sponsor: Hellenic Oncology Research Group

Target Recruit Count: 34

Registration Number: NCT01985841

Locations: 🇬🇷
"IASO" General Hospital of Athens, Athens, Greece
🇬🇷
"Metaxa's" Anticancer Hospital of Piraeus, 1st Dep of Medical Oncology, Piraeus, Greece
🇬🇷
University Hospital of Crete, Dep of Medical Oncology Heraklion, Greece, Heraklion, Greece

and more 3 locations

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Trastuzumab
Drug: Trastuzumab Emtansine
Drug: Pertuzumab
Drug: Paclitaxel
Drug: Epirubicin
Drug: Doxorubicin
Drug: Docetaxel
Drug: Cyclophosphamide
Drug: 5-Fluorouracil

First Posted Date: 2013-10-21

Last Posted Date: 2022-06-14

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 1846

Registration Number: NCT01966471

Locations: 🇨🇦
Princess Margaret Cancer Center, Toronto, Ontario, Canada
🇦🇺
Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia
🇯🇵
Niigata Cancer Ctr Hospital; Breast Surgery, Niigata, Japan

and more 292 locations

Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer

Phase 2

Completed

Conditions: Stage IA Pancreatic Cancer
Stage IB Pancreatic Cancer
Pancreatic Adenocarcinoma
Stage I Pancreatic Cancer
Stage II Pancreatic Cancer
Stage IIB Pancreatic Cancer
Resectable Pancreatic Carcinoma
Stage IIA Pancreatic Cancer
Stage III Pancreatic Cancer

Interventions: Procedure: 4-Dimensional Computed Tomography
Drug: Fluorouracil
Drug: Gemcitabine Hydrochloride
Other: Laboratory Biomarker Analysis
Drug: Leucovorin Calcium
Drug: Nelfinavir Mesylate
Biological: Oregovomab
Radiation: Stereotactic Body Radiation Therapy
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2013-10-10

Last Posted Date: 2023-10-10

Lead Sponsor: University of Nebraska

Target Recruit Count: 11

Registration Number: NCT01959672

Locations: 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States

S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Phase 1

Completed

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: Oxaliplatin
Drug: PEGPH20
Drug: Leucovorin
Drug: Irinotecan
Drug: 5-fluorouracil

First Posted Date: 2013-10-09

Last Posted Date: 2024-02-09

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 126

Registration Number: NCT01959139

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States
🇺🇸
Palo Alto Medical Foundation-Camino Division, Mountain View, California, United States

and more 150 locations

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Phase 3

Recruiting

Conditions: Metastatic Pancreatic Adenocarcinoma

Interventions: Drug: Fluorouracil
Drug: Glufosfamide

First Posted Date: 2013-10-07

Last Posted Date: 2024-12-31

Lead Sponsor: Eleison Pharmaceuticals LLC.

Target Recruit Count: 480

Registration Number: NCT01954992

Locations: 🇺🇸
Innovative Clinical Research Institute, Whittier, California, United States
🇺🇸
Gabrail Cancer Center Research, Canton, Ohio, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma

Phase 2

Withdrawn

Conditions: Hepatocellular Carcinoma
Lung Metastasis

Interventions: Drug: 5-fluorouracil
Drug: Mitomycin

First Posted Date: 2013-10-01

Last Posted Date: 2016-04-27

Lead Sponsor: Seoul National University Hospital

Registration Number: NCT01953406

Locations: 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of

Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy

Not Applicable

Withdrawn

Conditions: Stage IVB Colon Cancer
Recurrent Rectal Cancer
Stage IVB Rectal Cancer
Recurrent Colon Cancer
Stage IVA Colon Cancer
Stage IVA Rectal Cancer

Interventions: Biological: ziv-aflibercept
Drug: leucovorin calcium
Drug: irinotecan hydrochloride
Drug: fluorouracil

First Posted Date: 2013-09-13

Last Posted Date: 2014-07-21

Lead Sponsor: City of Hope Medical Center

Registration Number: NCT01941173

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States
🇺🇸
City of Hope- South Pasadena Cancer Center, South Pasadena, California, United States
🇺🇸
City of Hope Antelope Valley, Lancaster, California, United States

A Phase I Study of Aflibercept Plus FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) in Chinese Patients With Advanced Solid Malignancies

Phase 1

Completed

Conditions: Neoplasm Malignant

Interventions: Drug: Aflibercept AVE0005
Drug: Leucovorin
Drug: Irinotecan
Drug: 5-Fluorouracil

First Posted Date: 2013-08-29

Last Posted Date: 2015-01-07

Lead Sponsor: Sanofi

Target Recruit Count: 20

Registration Number: NCT01930552

Locations: 🇨🇳
Investigational Site Number 156002, Beijing, China
🇨🇳
Investigational Site Number 156001, Guangzhou, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy